S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
The single greatest medical breakthrough of all time? (Ad)
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
Canadian autoworkers ratify new labor agreement with Ford
The single greatest medical breakthrough of all time? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
The single greatest medical breakthrough of all time? (Ad)
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
Canadian autoworkers ratify new labor agreement with Ford
The single greatest medical breakthrough of all time? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
The single greatest medical breakthrough of all time? (Ad)
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
Canadian autoworkers ratify new labor agreement with Ford
The single greatest medical breakthrough of all time? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
The single greatest medical breakthrough of all time? (Ad)
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
Canadian autoworkers ratify new labor agreement with Ford
The single greatest medical breakthrough of all time? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
NASDAQ:ACHN

Achillion Pharmaceuticals (ACHN) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$1.01
$1.01
50-Day Range
$6.76
$6.76
52-Week Range
$2.06
$7.01
Volume
N/A
Average Volume
8.44 million shs
Market Capitalization
$141.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ACHN stock logo

About Achillion Pharmaceuticals (NASDAQ:ACHN) Stock

Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in New Haven, Connecticut.


ACHN Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
ACHN_old Historical Data
Xunlei Ltd Adr (XNET)
G1 Therapeutics Inc (GTHX)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Alexion Pharmaceuticals Is On Sale
Achillion shareholders back Alexion takeover
Achillion's (ACHN) Danicopan Gets EMA's PRIME Tag for PNH
Achillion Pharmaceuticals EPS beats by $0.02
See More Headlines
Receive ACHN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achillion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACHN Company Calendar

Last Earnings
11/07/2019
Today
9/24/2023

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ACHN
CUSIP
00448Q20
Fax
N/A
Employees
56
Year Founded
N/A

Profitability

Net Income
$-70,270,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.92 per share

Miscellaneous

Free Float
N/A
Market Cap
$141.45 million
Optionable
Optionable
Beta
1.59
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Joseph Truitt (Age 54)
    Pres, CEO & Director
  • Ms. Martha E. Manning (Age 64)
    Exec. VP, Gen. Counsel & Corp. Sec.
  • Mr. Brian R. Di Donato (Age 52)
    CFO, SVP & Treasurer
  • Mr. Paul Firuta (Age 53)
    Exec. VP & COO
  • Dr. Kevin P. Malobisky
    Sr. VP of Regulatory Affairs, Quality & Compliance













ACHN Stock - Frequently Asked Questions

How were Achillion Pharmaceuticals' earnings last quarter?

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) issued its quarterly earnings data on Thursday, November, 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.02.

What other stocks do shareholders of Achillion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Achillion Pharmaceuticals investors own include Chesapeake Energy (CHKAQ), Skyworks Solutions (SWKS), Madrigal Pharmaceuticals (MDGL), Noble (NE), ACADIA Pharmaceuticals (ACAD), Gilead Sciences (GILD), Eiger BioPharmaceuticals (EIGR), Iconix Brand Group (ICON), Celldex Therapeutics (CLDX) and Edap Tms (EDAP).

What is Achillion Pharmaceuticals' stock symbol?

Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."

What is Achillion Pharmaceuticals' stock price today?

One share of ACHN stock can currently be purchased for approximately $1.01.

How much money does Achillion Pharmaceuticals make?

Achillion Pharmaceuticals (NASDAQ:ACHN) has a market capitalization of $141.45 million. The biopharmaceutical company earns $-70,270,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis.

How can I contact Achillion Pharmaceuticals?

Achillion Pharmaceuticals' mailing address is 300 GEORGE STREET, NEW HAVEN CT, 06511. The official website for the company is www.achillion.com. The biopharmaceutical company can be reached via phone at 203-624-7000.

This page (NASDAQ:ACHN) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -